Protalix Biotherapeutics IncNYSE American:PLX
- LAST PRICE1.0600
- TODAY'S CHANGE (%)-0.0300 (-2.7523%)
- Bid / Lots1.0600/ 78
- Ask / Lots1.0700/ 13
- Open / Previous Close1.0900 / 1.0900
- Day Range
- 52 Week Range
- Volume63,387
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PLX |
|---|---|---|
| 09:32 ET | 667 | 1.09 |
| 09:34 ET | 404 | 1.1 |
| 09:39 ET | 3220 | 1.11 |
| 09:48 ET | 720 | 1.103 |
| 09:56 ET | 16617 | 1.09 |
| 10:03 ET | 100 | 1.09 |
| 10:10 ET | 200 | 1.0902 |
| 10:14 ET | 500 | 1.1 |
| 10:15 ET | 100 | 1.09 |
| 10:28 ET | 100 | 1.09 |
| 10:39 ET | 2245 | 1.09 |
| 10:42 ET | 100 | 1.09 |
| 10:55 ET | 100 | 1.09 |
| 10:57 ET | 600 | 1.095 |
| 11:00 ET | 100 | 1.09 |
| 11:11 ET | 100 | 1.09 |
| 11:13 ET | 100 | 1.0914 |
| 11:20 ET | 500 | 1.0954 |
| 11:27 ET | 100 | 1.09 |
| 11:36 ET | 1812 | 1.09 |
| 11:40 ET | 9443 | 1.08 |
| 11:42 ET | 837 | 1.09 |
| 11:47 ET | 200 | 1.08 |
| 11:56 ET | 100 | 1.08 |
| 12:03 ET | 200 | 1.08 |
| 12:05 ET | 250 | 1.08 |
| 12:07 ET | 100 | 1.08 |
| 12:09 ET | 200 | 1.08 |
| 12:18 ET | 100 | 1.08 |
| 12:21 ET | 100 | 1.08 |
| 12:36 ET | 500 | 1.085 |
| 12:39 ET | 100 | 1.08 |
| 12:45 ET | 100 | 1.08 |
| 12:59 ET | 100 | 1.08 |
| 01:01 ET | 100 | 1.08 |
| 01:03 ET | 2707 | 1.07 |
| 01:06 ET | 115 | 1.07 |
| 01:08 ET | 1814 | 1.07 |
| 01:10 ET | 6403 | 1.07 |
| 01:12 ET | 4237 | 1.07 |
| 01:19 ET | 100 | 1.0699 |
| 01:21 ET | 402 | 1.06 |
| 01:28 ET | 200 | 1.06 |
| 01:30 ET | 200 | 1.065 |
| 01:35 ET | 100 | 1.06 |
| 01:44 ET | 100 | 1.06 |
| 01:48 ET | 278 | 1.06 |
| 01:53 ET | 2525 | 1.065 |
| 01:55 ET | 200 | 1.07 |
| 01:57 ET | 100 | 1.06 |
Sep 20, 2024
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing, from 8:35AM ET on Friday Sep 20, 2024 by Dow Jones
8:35AM ET on Friday Sep 20, 2024 by Dow Jones
Sep 17, 2024
Sep 16, 2024
Life Sciences Virtual Investor Forum Agenda Announced for September 19th, from 12:07PM ET on Monday Sep 16, 2024 by Dow Jones
12:07PM ET on Monday Sep 16, 2024 by Dow JonesProtalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024, from 8:35AM ET on Monday Sep 16, 2024 by Dow Jones
8:35AM ET on Monday Sep 16, 2024 by Dow Jones
Sep 4, 2024
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference, from 6:50AM ET on Wednesday Sep 04, 2024 by Dow Jones
6:50AM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Protalix Biotherapeutics Inc | 80.2M | -5.3x | --- |
Cidara Therapeutics Inc | 76.2M | -0.4x | --- |
Bioqual Inc | 60.4M | 63.1x | -25.28% |
MDxHealth SA | 69.3M | -1.4x | --- |
MEI Pharma Inc | 19.1M | 1.1x | --- |
Sorrento Therapeutics Inc | 2.0M | 0.0x | --- |
Company Information
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.
Contact Information
- Headquarters
- 2 University Plaza, Suite 100HACKENSACK, NJ, United States 07601
- Phone
- 201-696-9345
- Fax
- 845-818-3588
Executives
- Independent Chairman of the Board
- Eliot Forster
- President, Chief Executive Officer, Director
- Dror Bashan
- Chief Financial Officer, Senior Vice President, Treasurer, Secretary
- Eyal Rubin
- Senior Vice President - Operations
- Yaron Naos
- Independent Director
- Amos Bar Shalev
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $80.2M |
|---|---|
Revenue (TTM) | $38.1M |
Shares Outstanding | 73.5M |
Protalix Biotherapeutics Inc does not pay a dividend. | |
Beta | 0.69 |
EPS | $-0.20 |
Book Value | $0.46 |
P/E Ratio | -5.3x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -38.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
